ENTA
Enanta Pharmaceuticals Inc
11.90$
-1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +58.3% | +14.3% | +16.1% | +26.8% | +18.3% | +0.2% | -10.2% | -13.7% | +21.5% | -18.5% | -25.5% | |
| – | +58.0% | +36.0% | +2.4% | +59.9% | +5.6% | +8.7% | -27.0% | -2.3% | +35.6% | -29.1% | -31.9% | |
| – | -29.2% | -23.7% | +296.2% | -2.7% | -19.8% | +70.1% | -34.3% | -23.1% | +94.1% | -56.4% | -13.3% | |
| – | +60.0% | +44.7% | +6.5% | +38.0% | +8.6% | +15.3% | -36.9% | +2.1% | +48.4% | -32.9% | -23.9% | |
| – | +249.8% | -18.3% | -17.3% | +533.2% | -23.6% | -54.2% | +158.9% | -19.4% | -19.2% | -2.5% | -82.2% | |
| – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | +226.5% | +36.0% | +0.6% | +4.0% | +30.5% | -21.3% | +23.9% | +179.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +45.8% | +15.1% | +120.1% | -17.7% | +33.0% | +28.8% | +17.7% | +43.0% | +314.4% | +0.9% | -12.8% | |
| – | +41.3% | +17.7% | +166.0% | -23.6% | +41.1% | +6.8% | +49.7% | -17.5% | +110.5% | -8.4% | -15.6% | |
| – | -65.8% | +5.8% | +8.2% | – | – | – | -1.4% | -31.2% | +82.5% | +582.2% | -5.9% | |
| – | -17.7% | +118.9% | +10.0% | +27.8% | +41.0% | -14.2% | +66.3% | -37.1% | -31.7% | +95.3% | -75.7% | |
| – | – | -2.5% | +379.2% | +113.6% | +0.0% | – | – | – | – | – | – | |
| – | +58.9% | +14.3% | +11.8% | +30.5% | +17.5% | -1.5% | -12.3% | -19.6% | -32.6% | -40.6% | -49.8% | |
| – | – | +362.3% | +64.1% | +158.7% | +39.5% | -22.1% | -61.9% | -250.6% | – | – | – | |
| – | +0.6% | -0.4% | +1.0% | +6.4% | +1.5% | -4.9% | +1.2% | +2.1% | +1.8% | +0.9% | +0.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.